JP2023524911A5 - - Google Patents

Info

Publication number
JP2023524911A5
JP2023524911A5 JP2023509461A JP2023509461A JP2023524911A5 JP 2023524911 A5 JP2023524911 A5 JP 2023524911A5 JP 2023509461 A JP2023509461 A JP 2023509461A JP 2023509461 A JP2023509461 A JP 2023509461A JP 2023524911 A5 JP2023524911 A5 JP 2023524911A5
Authority
JP
Japan
Prior art keywords
seq
peptide
fusion inhibitor
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023509461A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524911A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/028667 external-priority patent/WO2021216891A2/en
Publication of JP2023524911A publication Critical patent/JP2023524911A/ja
Publication of JP2023524911A5 publication Critical patent/JP2023524911A5/ja
Pending legal-status Critical Current

Links

JP2023509461A 2020-04-24 2021-04-22 Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としての脂質－ペプチド融合物阻害剤 Pending JP2023524911A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063015479P 2020-04-24 2020-04-24
US63/015,479 2020-04-24
PCT/US2021/028667 WO2021216891A2 (en) 2020-04-24 2021-04-22 Lipid-peptide fusion inhibitors as sars-cov-2 antivirals

Publications (2)

Publication Number Publication Date
JP2023524911A JP2023524911A (ja) 2023-06-13
JP2023524911A5 true JP2023524911A5 (enExample) 2024-05-07

Family

ID=78270019

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023509461A Pending JP2023524911A (ja) 2020-04-24 2021-04-22 Ｓａｒｓ－ｃｏｖ－２抗ウイルス薬としての脂質－ペプチド融合物阻害剤

Country Status (9)

Country Link
US (1) US20230159597A1 (enExample)
EP (1) EP4139330A4 (enExample)
JP (1) JP2023524911A (enExample)
KR (1) KR20230028719A (enExample)
CN (1) CN115916806A (enExample)
BR (1) BR112022021528A2 (enExample)
CA (1) CA3175831A1 (enExample)
IL (1) IL297498A (enExample)
WO (1) WO2021216891A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4419140A1 (en) 2021-10-22 2024-08-28 Wisconsin Alumni Research Foundation Peptides that inhibit infection by sars-cov-2, the virus that causes covid-19 disease
WO2024016011A2 (en) * 2022-07-15 2024-01-18 The Trustees Of Columbia University In The City Of New York Broad spectrum inhibition of human coronaviruses by lipopeptides derived from the c-terminal heptad repeat of betacoronaviruses
WO2025231157A2 (en) * 2024-04-30 2025-11-06 Decoy Therapeutics Inc. New anti-viral therapeutic peptides, conjugates, and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004277370A1 (en) * 2003-04-28 2005-04-14 Sequoia Pharmaceuticals, Inc. Antiviral agents for the treatment, control and prevention of infections by coronaviruses
US20080027006A1 (en) * 2004-02-12 2008-01-31 The Regents Of The University Of Colorado Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
WO2010089129A1 (en) * 2009-02-06 2010-08-12 Cormus Srl Inhibitors of viral fusion and uses thereof
EP2603241A2 (en) * 2010-08-11 2013-06-19 Jv Bio Srl Multimeric inhibitors of viral fusion and uses thereof
CN104151403B (zh) * 2013-04-08 2020-11-03 中国医学科学院药物研究所 一类多肽或其衍生物、及其在流感病毒感染中的应用
WO2015171924A2 (en) * 2014-05-07 2015-11-12 Cornell University Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
WO2017015457A1 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
US20180243225A1 (en) * 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
EP4114431A2 (en) * 2020-03-04 2023-01-11 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized sars-cov-2 peptides and uses thereof

Similar Documents

Publication Publication Date Title
Zhirnov et al. Aprotinin and similar protease inhibitors as drugs against influenza
RU2524304C2 (ru) Применение соли ацетилсалициловой кислоты для лечения вирусных инфекций
US20180305412A1 (en) Compositions and methods for treating diseases by inhibiting exosome release
JPH09502424A (ja) 安定化製薬性ペプチド組成
JP2009102370A (ja) グリシルリジン酸及び抗ウイルス活性を有する蛋白質を少なくとも一つ含む、抗ウイルス薬剤組成物
WO2022081711A4 (en) Lipopeptide fusion inhibitors as sars-cov-2 antivirals
JP2024504225A5 (enExample)
US20240398893A1 (en) Anti-coronavirus polypeptide as well as derivative and application thereof
WO2023232095A9 (zh) 一种基于病毒阻断剂的口腔喷雾制剂及其用途
JP2023527791A (ja) ウイルス性呼吸器感染症を治療するための方法
CN114870061B (zh) 一种基于病毒阻断剂的空气喷雾剂及其用途
WO2021207848A1 (en) Mers-cov vaccine
Gao et al. Antiviral peptides with in vivo activity: development and modes of action
JP2022551813A5 (enExample)
JPH06507386A (ja) 治療用ペプチド
EP1797112B1 (en) Inhibitors of hepatitits c virus
US20240115667A1 (en) Diphenhydramine and lactoferrin for prevention and treatment of covid-19
EP4313103A1 (en) Compounds for use in the treatment of sinusitis, pneumonia or otitis
US20240261392A1 (en) Compositions and methods to increase coronavirus immune response
CN120813372A (zh) 针对冠状病毒的疫苗
US6610304B1 (en) Liposomes containing multiple branch peptide constructions for use against human immunodeficiency virus
WO2022135622A3 (es) Péptidos para el tratamiento de infecciones respiratorias de origen viral
EP3994266A1 (en) Compositions and methods useful for ebola virus infection
WO2024096742A1 (en) SARS-CoV-2 BINDING POLYPEPTIDE
WO2024096743A1 (en) Sars-cov-2 binding antibody